Fexofenadine: A Viewpoint by Stanley P. Galant

ISSN： 0012-6667

Source： Drugs, Vol.55, Iss.2, 1998-02, pp. : 275-276

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Fexofenadine

By Markham A. Wagstaff A.J.

Drugs, Vol. 55, Iss. 2, 1998-02 ,pp. : 269-274

Adis International

Access to resources Recommend Favorite

Travoprost/Timolol: A Viewpoint by Anastasios G.P. Konstas

By Konstas Anastasios G.P.

Drugs & Aging, Vol. 23, Iss. 7, 2006-01 ,pp. : 598-599

Adis International

Access to resources Recommend Favorite

Triflusal: A Viewpoint by José P. De La Cruz

By De La Cruz P.

Drugs, Vol. 55, Iss. 6, 1998-06 ,pp. : 834-835

Adis International

Access to resources Recommend Favorite

Developing a method for the quantitative determination of the P-glycoprotein activity marker fexofenadine in blood plasma

By Ramenskaya G. Skuridina E. Krasnykh L.

Pharmaceutical Chemistry Journal, Vol. 40, Iss. 12, 2006-12 ,pp. : 686-689

Springer Publishing Company

Access to resources Recommend Favorite

Tramadol Extended-Release Tablets: A Viewpoint by Mellar P. Davis

By Davis Mellar P.

Drugs, Vol. 66, Iss. 15, 2006-01 ,pp. : 2028-2030

Adis International

Access to resources Recommend Favorite